A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia

Inclusion Criteria:

• Males or females 35 to 75 years of age at the time of signing the informed consentform (ICF).

• Considered to be generally healthy based on medical history, physical examination,and the re-sults of vital signs, electrocardiogram, and clinical laboratory testsperformed during the screening visit, as judged by the investigator.

• Body mass index (BMI) 20 to 35 kilogram per meter square (kg/m2) (both inclusive) atscreening.

• Serum uric acid levels greater than or equal to (≥) 6.8 miligram per decileter (mg/dL) to less than or equal (≤) 12 mg/dL on 2 consecutive screening samples (thefirst at the screening visit [V1], and the second taken at V2 [day -1]; samples atleast 7 days apart).

Exclusion Criteria:

• Female who is pregnant, breastfeeding, or intends to become pregnant or is ofchildbearing po-tential and not using an adequate contraceptive method.

• Male of reproductive age who, or whose female partner(s), is not using an adequatecontraceptive method.

• Present or prior history of gout, or present or prior use of serum Uric acid (sUA)lowering medication.

• Serious cardiovascular or hepatic disease, current or past malignancies, or chronicdebilitating neurologic, gastrointestinal, or inflammatory diseases.

• History or current diagnosis of chronic history kidney disease.

• Screening alanine transaminase (ALT) or aspartate aminotransferase (AST) valuesgreater than (>) 2 multiply by (×) upper limit normal (ULN) or total bilirubin >1.5×ULN.